Results from DENALI Part 1b show an Objective Response Rate (ORR) of ~35% in response-evaluable, heavily-pretreated patients with Cyclin E1+ ...

Ovarian cancer is caused by a harmful ... fallopian tubes and they include low grade and high grade tumor types. These cancers should be treated with surgery, radiation, targeted therapy, and ...

Toxic effects for which a specific grade is not listed are generally assessed ... Although proteins remain the most common cancer biomarkers, other molecules, such as circulating cell-free tumour DNA, ...

A mathematical modeling study conducted in Germany suggests that ovarian cancer incidence could be reduced and health care ...

Oral squamous cell carcinoma (OSCC) is an aggressive cancer, with prognosis influenced by clinical variables as well grading systems and perineural invasion (PNI), which are associated to poorer ...

Traditional approaches to prostate cancer screening involve blood tests, MRI, and biopsies. However, in addition to being ...

evaluate these biomarkers in pre-clinical cancer models. Significant efforts are directed towards validating biomarkers for early prediction of treatment response, with the focus on new targeted ...

In contrast, the sensitivity of IFSH for predicting final surgical margin status was low, at 21.7%. This indicates that while ...

Toxicity was moderate: febrile neutropenia, grade 3 infection ... (fluorescence in situ hybridization [FISH] positive) ovarian cancer progressing under taxane/carboplatin chemotherapy or in ...

Research on the development, physiology and pathophysiology of reproductive disorders is important, as evidence suggests that many adult-onset diseases can be traced back to disruptions during early ...

A pioneering study has unveiled the Au-HN-1 nanosystem, a cutting-edge approach that promises to transform the diagnosis and treatment of tongue squamous cell carcinoma (TSCC). By harnessing gold ...

Imfinzi (durvalumab) was recommended by NICE for NHS use in combination with etoposide plus either carboplatin or cisplatin for adults with untreated extensive-stage small cell lung cancer (ES-SCLC).